Marriage Counselors in Royal Oak, MI Accepting Medicare
6 Marriage Counselors found. Showing 1 - 6
 Anita Jean Meyers Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 4949 Coolidge Hwy, Royal Oak, MI 48073 Phone: 248-423-2454 Fax: 248-423-2576 |
Jennifer Marie Bak, PH.D., LMFT Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 1208 Englewood Ave, Royal Oak, MI 48073 Phone: 248-462-3627 |
Dr. Erika London Bocknek, PHD, LMFT Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 27172 Wood Avenuve, Suite 200, Royal Oak, MI 48067 Phone: 248-546-0407 |
Mrs. Margie O'connor, LMSW Marriage & Family Therapist Medicare: Accepting Medicare Assignments Practice Location: 27172 Woodward Ave, #200, Royal Oak, MI 48067 Phone: 248-546-0407 Fax: 248-546-1925 |
 Neil Kosofsky, LLMFT Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 27172 Woodward Ave, Royal Oak, MI 48067 Phone: 248-546-0407 Fax: 248-548-1925 |
Chanchal Tandon, LMFT Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 1818 E Hudson Ave, Royal Oak, MI 48067 Phone: 850-766-6534 |
News Archive
Two research studies to examine factors related to early development of breast cancer
The Cancer Institute of New Jersey and its System Partner Meridian Health are working together on two research studies to examine factors related to the early development of breast cancer.
Researchers make breakthrough in understanding enzymes that assemble the antibiotic enacyloxin
One of the WHO's three critical priority pathogens, Acinetobacter baumannii, for which new antibiotics are urgently needed is one step closer to being tackled, as researchers from the Department of Chemistry - University of Warwick have made a breakthrough in understanding the enzymes that assemble the antibiotic enacyloxin.
Researchers discover a new mechanism of long-lasting pain relief
A group of researchers from Charité - Universitätsmedizin Berlin has discovered a new mechanism of long-lasting pain relief.
Santen announces Phase III results of sirolimus intravitreal injections in non-infectious posterior segment uveitis patients
Santen Inc., the U.S. subsidiary of global ophthalmic pharmaceutical company Santen Pharmaceutical Co., Ltd. (Osaka, Japan), today announced that SAKURA (Study Assessing double‐masKed Uveitis tReAtment) Study 1, the first of two Global Phase III studies evaluating intravitreal injections of sirolimus in patients with non-infectious posterior segment uveitis (NI-PSU), met its primary endpoint.
› Verified 7 days ago
Clinical Social Workers
Occupational Therapists
Psychologists
Counselors
Pharmacists
Dentists